Want to see BHST full AI Analyst Report?
BHST Stock Chart & Stats
$2.00
$0.11(5.73%)
At close: 4:00 PM EDT
$2.00
$0.11(5.73%)
Day’s Range― - ―
52-Week Range$1.82 - $12.80
Previous Close$2.03
Volume137.38K
Average Volume (3M)78.84K
Market Cap
$45.34M
Enterprise Value$66.16
Total Cash (Recent Filing)$16.22M
Total Debt (Recent Filing)$17.55M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 30, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding22,667,843
10 Day Avg. Volume86,360
30 Day Avg. Volume78,844
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside350.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$42.89M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Gross MarginRapid multi-year revenue expansion and a gross margin near 59% indicate meaningful product demand and attractive unit economics. If maintained while the company scales, this combination could support operating leverage and improve the pathway toward sustainable profitability.
CDMO Agreement Expands Platform MonetizationThe agreement validates Botanical Synthesis beyond consumer nutraceuticals and creates a potential recurring manufacturing revenue stream. It also positions the company in premium fragrance ingredients, although production timing and final economics remain subject to execution and negotiations.
Improved Liquidity And Stronger Balance SheetThe substantial increase in cash and return to positive equity provide greater capacity to fund CDMO development and absorb operating volatility. Improved liquidity also reduces immediate financing pressure while management works toward targeted EBITDA breakeven in 2027.
Bears Say
Persistent Losses And Cash BurnDespite strong revenue growth and gross margins, BHST has not reached operating scale or break-even. Continued net losses and negative operating and free cash flow require financing capacity, creating dilution or liquidity risk if profitability is delayed.
Reduced 2026 Revenue And EBITDA OutlookLower guidance signals weaker near-term top-line visibility and a slower contribution from the consumer business. The wider EBITDA loss indicates that marketing changes and CDMO capacity investment are currently increasing costs before the expected longer-term benefits materialize.
Rising Debt And Uncertain CDMO EconomicsHigher debt reduces flexibility while the company remains loss-making, and the major CDMO opportunity has not yet established firm cash-flow terms. Delayed production, absent upfront payments and unresolved royalties could extend the funding gap before contract economics become visible.
BioHarvest Sciences News
BHST FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was $1.82 and its highest was $12.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is $45.34M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Nov 30, 2026 which is in 94 days.
How were BioHarvest Sciences’s earnings last quarter?
BioHarvest Sciences released its earnings results on Aug 11, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.052.
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.14.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
BioHarvest Sciences reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went down -1.19%.
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (350.00% Upside)
$9.00 (350.00% Upside)
Blogger Sentiment
Neutral
BHST Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.33%
Trailing 12-Months
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
BHST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced significant strategic progress and validation—most notably the major fragrance CDMO contract, stronger cash position, and government-backed technology grants—against near-term revenue guidance cuts, higher operating expenses, and continued adjusted EBITDA losses. Management is pivoting resources toward higher-margin CDMO opportunities and capacity build-out, accepting lower near-term product revenue (VINIA) in order to pursue longer-term profitability and scale. Key positives are the sizeable contract pipeline and material cash increase; key negatives are reduced 2026 top-line guidance and short-term profitability pressures stemming from reallocated marketing and development spend.View all BHST earnings summariesBHST Stock 12 Month Forecast
Average Price Target
$9.00
▲(350.00% Upside)
Technical Analysis
Ownership Overview
0.08% Insiders
0.05% Mutual Funds
6.82% Other Institutional Investors
93.05% Public Companies and
Individual Investors